Skip to Content

'
James L. Abbruzzese, M.D., F.A.C.P., F.A.S.C.O., D.Sc.(hon.)

Present Title & Affiliation

Primary Appointment

Department Chair, Gastrointestinal Medical Oncology and Digestive Diseases, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1978 University of Chicago - Pritzker School of Medicine, Chicago, IL, MD, Medicine
1974 Fairfield University, Fairfield, CT, BS, Biology

Experience/Service

Administrative Appointments/Responsibilities

Department Chair, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000-present

Endowed Positions

Waun Ki Hong Distinguished Chair in Translational Oncology, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, 2011-present
M.G. and Lillie A. Johnson Chair for Cancer Treatment and Research, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003-2011
Annie Laurie Howard Research Distinguished Professorhip, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2000-2003

Institutional Committee Activities

Chairman, Search Committee for the Chairman of the Department of Thoracic and Head and Neck, 2004-2005
Member, Multidisciplinary Research Advisory Committee, 2002-2008

Honors and Awards

2008 ASCO Statesman Award, American Society of Clinical Oncology
2005 3rd Annual Sidney E. Salmon Memorial Pancreatic Cancer Lectureship, University of Arizona Cancer Center
2002 The 14th Annual Robert and Alma Moreton Lectureship in Oncology, Scott and White Clinic

Selected Publications

Peer-Reviewed Original Research Articles
1. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed? J Clin Oncol. e-Pub 11/5/2012. PMID: 23129736.
2. Li L, Othman M, Rashid A, Wang H, Li Z, Katz MH, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB, Wang H. Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells. Histopathology. e-Pub 9/4/2012. PMID: 23134473.
3. Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, Wolff RA, Abbruzzese JL, Lee JE, Fleming JB. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg 215(1):41-51, 7/2012. PMID: 22608401.
4. Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, Crane CH, Abbruzzese J, Evans D, Spitz MR. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage 38(6):894-902, 6/2012. PMCID: PMC2795073.
5. Weng S, Wang H, Chen W, Katz MH, Chatterjee D, Lee JE, Pisters PW, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Overexpression of Protein Phosphatase 4 Correlates with Poor Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev, 6/2012. PMID: 22665577.
6. Friday B, Lassere Y, Meyers CA, Mita A, Abbruzzese JL, Thomas MB. A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors. Anticancer Res 32(5):1689-96, 5/2012. PMID: 22593447.
7. Ramanathan RK, Abbruzzese JL, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S, Von Hoff DD. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol, 5/2012. PMID: 20461382.
8. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer, 5/2012. PMID: 22605518.
9. Tomblyn MB, Goldman BH, Thomas CR, Benedetti JK, Lenz HJ, Mehta V, Beeker T, Gold PJ, Abbruzzese JL, Blanke CD, for the SWOG GI Committee. Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414). J Thorac Oncol, 4/2012. PMID: 22481235.
10. Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 5(1):15, 4/2012. PMID: 22475564.
11. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer. Clin Cancer Res. e-Pub 3/2012. PMID: 22465831.
12. Chatterjee D, Katz MH, Rashid A, Wang H, Iuga AC, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Crane CH, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol 36(3):409-17, 3/2012. PMID: 22301497.
13. Chatterjee D, Rashid A, Wang H, Katz MH, Wolff RA, Varadhachary GR, Lee JE, Pisters PW, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Tumor Invasion of Muscular Vessels Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma Who Have Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Am J Surg Pathol, 1/2012. PMID: 22301496.
14. Overman MJ, Hu CY, Kopetz S,Abbruzzese JL, Wolff RA, Chang GJ. A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease. Ann Surg Oncol, 12/2011. PMID: 22187121.
15. Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, Lee JE, Pisters PW, Vauthey JN, Katz MH, Gomez HF, Evans DB,Abbruzzese JL, Fleming JB, Wang H. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer, 12/2011. PMID: 22180096.
16. Katz MH, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, Pisters PW, Lee JE, Vauthey JN, Abdalla EK, Wolff R,Abbruzzese JL, Varadhachary G, Chopin-Laly X, Charnsangavej C, Fleming JB. Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer. J Gastrointest Surg, 11/2011. PMID: 22065318.
17. Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, Balachandran A, Varadhachary GR, Pisters PW, Wang H, Gomez HF,Abbruzzese JL, Fleming JB, Wang H. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol, 11/2011. PMID: 22050964.
18. Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, Lee JE, Pisters PW, Vauthey JN, Crane C, Gomez HF,Abbruzzese JL, Fleming JB, Wang H. Histologic grading the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: A predictor for patient outcome. Cancer, 10/2011. PMID: 22028089.
19. Chang DZ, Ma Y, Ji B, Wang H, Deng D, Liu Y,Abbruzzese JL, Liu Y, Logsdon CD, Hwu P. Mast Cells in Tumor Microenvironment Promotes the in vivo Growth of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res, 10/2011. PMID: 21976550.
20. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S,Abbruzzese JL. Clinical and Prognostic Implications of Plasma Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Patients With Hepatocellular Carcinoma. J Clin Oncol, 9/2011. PMID: 21911725.
21. Dong X, Li Y, Tang H, Chang P, Hess KR, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol. e-Pub 8/16/2011. PMID: 21852217.
22. Kaseb AO,Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A, Morris JS. I-CLIP: Improved Stratification of Advanced Hepatocellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP Score. Oncology 80(5-6):373-381, 8/2011. PMID: 21822028.
23. Abbruzzese JL. Introducing CCR Perspectives in Drug Approval. Clin Cancer Res 17(15):4929, 8/2011. PMID: 21791634.
24. Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon A,Abbruzzese JL, Chiao PJ. Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1. J Natl Cancer Inst 103(15):1190-204, 8/2011. PMCID: PMC3149044.
25. Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA,Abbruzzese JL, Fogelman DR. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol, 8/2011. PMID: 21850466.
26. Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao P,Abbruzzese JL, Melisi D. Anti-VEGF Treatment Resistant Pancreatic Cancers Secrete Proinflammatory Factors that Contribute to Malignant Progression by Inducing an EMT cell phenotype. Clin Cancer Res, 7/2011. PMID: 21737511.
27. Estrella JS, Rashid A, Fleming JB, Katz MH, Lee JE, Wolf RA, Varadhachary GR, Pisters PW, Abdalla EK, Vauthey JN, Wang H, Gomez HF, Evans DB,Abbruzzese JL, Wang H. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer, 7/2011. PMID: 21735446.
28. Kim MP, Fleming JB, Wang H,Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE. ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. PLoS One 6(6):e20636, 6/2011. PMCID: PMC3113804.
29. Dong X, Li Y, Chang P, Hess KR,Abbruzzese JL, Li D. DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Mol Carcinog, 6/2011. PMID: 21681824.
30. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE,Abbruzzese JL, Wolff RA. Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression. J Clin Oncol, 6/2011. PMID: 21709185.
31. Tanaka M, Chang P, Li Y, Li D, Overman M, Maru DM, Sethi S, Phillips JK, Bland G,Abbruzzese JL, Eng C. Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer. Clin Cancer Res, 5/2011. PMID: 21551253.
32. Bernatchez C, Zhu K, Li Y, Andersson H, Ionnides C, Fernandez-Vina M, Cano P, Cooper L,Abbruzzese JL, Hwu P, Chang DZ, Radvanyi LG. Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. Vaccine 29(16):3021-30, 4/2011. PMCID: PMC3070784.
33. Fogelman D, Jafari M, Varadhachary GR, Xiong H, Bullock S, Ozer H, Lin E, Morris J, Cunningham P, Bennett B,Abbruzzese JL, Wolff RA. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol, 4/2011. PMID: 21479635.
34. Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F,Abbruzzese JL. Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer. Anticancer Res 31(4):1417-20, 4/2011. PMID: 21508395.
35. Varadhachary GR, Spector Y,Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Bocker Edmonston T, Raber MN. Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown Primary (CUP). Clin Cancer Res, 4/2011. PMID: 21531815.
36. Dong X, Li Y, Chang P, Tang H, Hess KR,Abbruzzese JL, Li D. Glucose Metabolism Gene Variations Modulate the Risk of Pancreatic Cancer. Cancer Prev Res (Phila), 3/2011. PMID: 21411499.
37. Tanaka M, Okazaki T, Suzuki H, Abbruzzese JL, Li D. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer 117(4):744-51, 2/15/2011. e-Pub 10/4/2010. PMCID: PMC3017663.
38. Tang H, Dong X, Hassan MM,Abbruzzese JL, Li D. Body Mass Index and Obesity- and Diabetes-associated Genes and Risk for Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev, 2/2011. PMID: 21357378.
39. Dong X, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer 117(3):480-91, 2/2011. PMID: 20845477.
40. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB,Abbruzzese JL, Gomez HF, Evans DB, Wang H. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 117(4):734-43, 2/2011. PMID: 20922806.
41. Dong X, Li Y, Hess KR,Abbruzzese JL, Li D. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist 16(1):61-70, 1/2011. PMID: 21212431.
42. Basha R, Baker CH, Sankpal UT, Ahmad S, Safe S,Abbruzzese JL, Abdelrahim M. Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid. Front Biosci (Schol Ed) 3:797-805, 1/2011. PMID: 21196413.
43. Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A,Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer, 12/2010. PMCID: PMC3066286.
44. Logsdon CD, Abbruzzese JL. Chemoprevention of pancreatic cancer: ready for the clinic? Cancer Prev Res (Phila) 3(11):1375-8, 11/2010. PMCID: PMC3051830.
45. Tanaka M, Javle M, Dong X, Eng C,Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 116(22):5325-35, 11/2010. PMCID: PMC2966859.
46. Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, Shi Y, Abbruzzese JL, Konopleva M, Andreeff M, Marini FC. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 12(5):615-25, 9/2010. PMID: 20230221.
47. Li D,Abbruzzese JL. New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res 16(17):4313-8, 9/2010. PMCID: PMC2932833.
48. Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, de Bono J, Norris J, Matsushita H, Mita A, Rowinsky EK. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. Invest New Drugs, 9/2010. PMID: 20839029.
49. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology 139(2):464-73, 473.e1-3, 8/2010. PMCID: PMC2910789.
50. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28(22):3605-10, 8/2010. PMCID: PMC2917315.
51. Peng L, Liang J, Wang H, Song X, Rashid A, Gomez HF, Corley LJ, Abbruzzese JL, Fleming JB, Evans DB, Wang H. High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res 16(14):3734-42, 7/2010. PMID: 20628027.
52. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA,Abbruzzese JL. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 10:368, 7/2010. PMCID: PMC2910694.
53. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17(7):1794-801, 7/2010. PMCID: PMC2889288.
54. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49(4):474-9, 5/2010. PMID: 20397775.
55. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD,Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116(8):1938-46, 4/2010. PMID: 20166205.
56. Blanke CD, Chansky K, Christman KL, Hundahl SA, Issell BF, Van Veldhuizen PJ, Budd GT, Abbruzzese JL, Macdonald JS. S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. Am J Clin Oncol 33(2):117-20, 4/2010. PMCID: PMC2967385.
57. Abbruzzese JL, Eggermont AM, Rubin EH. Introducing new strategies in.. Clin Cancer Res 16(5):1347, 3/2010. PMID: 20179221.
58. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC,Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 116(6):1446-53, 3/2010. PMID: 20108336.
59. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs, 1/2010. PMID: 20107864.
60. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102(1):144-50, 1/2010. PMCID: PMC2813754.
61. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM,Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28(3):453-9, 1/2010. PMCID: PMC2815707.
62. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 16(1):320-9, 1/2010. PMCID: PMC2802655.
63. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese JL, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27(33):5660-9, 11/2009. PMID: 19858397.
64. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 4(11):1670-80, 10/2009. PMID: 19876027.
65. Melisi D, Ossovskaya V, Zhu C, Rosa R, Ling J, Dougherty PM, Sherman BM, Abbruzzese JL, Chiao PJ. Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. Clin Cancer Res 15(20):6367-77, 10/2009. PMID: 19808866.
66. Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA, Wong L, Ward JH, Abbruzzese JL, Blanke CD. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs 27(5):469-75, 10/2009. PMID: 18941712.
67. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2(137):482-488, 8/2009. PMCID: PMC2735093.
68. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 14(69):5820-5828, 7/2009. PMID: 19584296.
69. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL. Body mass index and survival in patients with pancretic cancer. JAMA 301(301):24, 6/2009. PMCID: PMC2760963.
70. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 27(16):2598-603, 6/2009. PMID: 19164203.
71. Shin S, Asano T, Yao Y, Zhang R, Claret FX, Korc M, Sabapathy K, Menter DG, Abbruzzese JL, Reddy SA. Activator Protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism. Mol Cancer Res 7(5):745-54, 5/2009. e-Pub 5/2009. PMID: 19435822.
72. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocelluarl carcinoma: a case-control study in the United States. Hepatology 49(5):1563-1570, 5/2009. PMID: 19399911.
73. Kopetz S, Abbruzzese JL. Barriers to Integrating Gene Profiling for Stage II Colon Cancer. Clin Cancer Res 15(24):7451-7452, 5/2009. PMID: 19996205.
74. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842-3849, 5/2009. e-Pub 4/2009. PMCID: PMC2709758.
75. Ng CS, Kodama Y, Mullani NA, Barron BJ, Wei W, Herbst RS, Abbruzzese JL, Charnsangavej C. Tumor blood flow measured by perfusion computed tomography and 150-labeled water poitron emission tomography: a comparision study. J Comput Assist Tomogr 33(3):460-465, May-Jun, 5/2009. PMID: 19478644.
76. Kopetz S, Abbruzzese JL. Hidden biases in an observational study of bevacizumab beyond progression. J Clin Oncol 27(10):1732-3; author reply 1733, 4/2009. e-Pub 3/2009. PMID: 19255299.
77. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4):836-847, 4/2009. e-Pub 2/2009. PMID: 19194760.
78. Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR, Abbruzzese JL, Li D. Significant Assocations of Mismatch Repair Gene Polymorphisms with Clinical Outcome of Pancreatic Cancer. J Clin Oncol 27(10):1592-9, 4/2009. e-Pub 2/2009. PMCID: PMC2668967.
79. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Acquisition of epithelial-mesenchymal transition phenotpye of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69(6):2400-2407, 3/2009. e-Pub 3/2009. PMCID: PMC2657919.
80. Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therpay by inhibiting survivin protien epxression. Mol Cancer Ther 8(3):533-542, 3/2009. e-Pub 3/2009. PMID: 19258429.
81. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma. J Clin Oncol 27(6):843-50, 2/2009. e-Pub 1/2009. PMID: 19139433.
82. Chen J, Li D, Killary AM, Sen S, Amos CI, Evans DB, Abbruzzese JL, Frazier ML. Polymorphisms of p16, p27, p73, and MDM2 Modulate Response and Survival of Pancreatic Cancer Patients Treated with Preoperative Chemoradiation. Ann Surg Oncol 16(2):431-9, 2/2009. e-Pub 11/2008. PMID: 19020940.
83. Wang H, Song X, Logsdon C, Zhou G, Evans DB, Abbruzzese JL, Hamilton SR, Tan TH, Wang H. Proteasome-Mediated Degradation and Functions of Hematopoietic Progenitor Kinase 1 in Pancreatic Cancer. Cancer Res 69(3):1063-70, 2/2009. e-Pub 1/2009. PMID: 19141650.
84. Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: A case-control study in the United States. J Hepatol 50(2):334-41, 2/2009. e-Pub 10/2008. PMCID: PMC2658718.
85. Li D, Suzuki H, Liu B, Morris J, Liu J, Okazaki T, Li Y, Chang P, Abbruzzese JL. DNA repair gene polymorphisms and risk of pancreatic cancer. Clin Cancer Res 2(15):740-6, 1/2009. PMCID: PMC2629144.

Abstracts
1. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarka FH. Acquisition of epithelial-mesenchymal tranition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of notch signaling pathway. Proc Am Assn Cancer Res 40:765 (#3165), 2009.
2. Li D, Morris J, Liu J, Hassan MM, Day RS, Bondy ML, Evans DB, Abbruzzese JL. Association of body mass index with risk, age of onset and survival of pancreatic cancer. Proc Am Assn Cancer Res 40:21 (#84), 2009.
3. Ma Y, Baoan J, Wang H, Liu Y, Deng D, Abbruzzese JL, Ulrich SE, Liu YJ, Hwu P, Logsdon C, Chang DZ. Characterization of evolving inflammatory status in microenviroment in a transgenic spontaneous PDAC model and coreelation with clinical outcomes in human PDAC patients. Proc Am Assn Cancer Res 40:281 (#1168), 2009.
4. Hideo S, Li Y, Dong X, Hassan MM, Hyodo I, Abbruzzese JL, Li D. Effect of IGF gene polymorphisms alone ore in interation with diabetes on the risk of pancreatic cancer. Proc Am Assn Cancer Res 40:511 (#2111), 2009.
5. Chio W, Arumugam T, Fournier K, Ramachandra V, Abbruzzese JL, Gallick G, Logsdon C, McConkey DJ. Gene expression profiling implicated EMT in global drug resistance in pancreatic cancer. Proc Am Assn Cancer Res 40:587 (#2425), 2009.
6. Parker PA, Baile W, Cohen L, Abbruzzese JL, Vardhahcary G, Ho L, PaPushin T, Dayao P, Lenzi R. Illness uncertainty, sense of coherence, and psychosocial adjustment in patients with pancreatic cancer. Annals of Behavioral Medicine 51, 2009.
7. Javle, MM, Reddy SA, Davis D, Xiong H, Vardhachary G, Fogelman, D, Kaseb A, Wolff RA, Abbruzzese JL. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer - the results of two prospective phase II studies. Proceedings American Association of Cancer Research 40:1053 (#4363), 2009.
8. Talantov D, Varadhachary G, Raber M, Jatkow T, Meng C, Hess K, Lenzi R, Spigel D, Greco A, Abbruzzese JL, Wang Y, Hainsworth J. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. Proc Am Assn Cancer Res 40:656 (#2718), 2009.
9. Wang H, Song X, Longsdon C, Abbruzzese JL, Evans D, Wang H. Overspression of Axl in pancreatic ductal carcinoma is associated with tumor invasion, metastasis and poor prognosis. Proc Am Assn Cancer Res 40:386 (#1613), 2009.
10. Melisi D, Xia Q, Abbruzzese JL, Chiao PJ. TGF-B activated kinase I (TAK1) is a drugable target for pancreatic cancer (PC) chemosensitization. Proc Am Assn Cancer Res 40:672 (#2783), 2009.
11. Hassan MM, Kaseb A, Li D, Moghazy D, Vauthey JN, Curley SA, Abdalla EK, Abbruzzese JL. The association betwenn diabetes mellitus and hepatocellular carcinoma. Proc Am Assn Cancer Res 40:519 (#2139), 2009.
12. Kaseb A, Harikumar KB, Junnmakkara AB, Deorukhkar A, Abbruzzese JL, Krishnan S, Aggarwal BB, Guha S. Tymoquinone-induced E2F-1 downregulation and induction of apoptosis enchances gemcitabine effects in pancreatic cancer. Pro Am Assn Cancer Res 66:666 (#2759), 2009.

Book Chapters
1. Varadhachary GR, Abbruzzese JL. Carcinoma of Unknown Primary. In: Harrison's Principles of Internal Medicine, 18th, 821-826, 2012.

Letters to the Editor
1. Kopetz S, Abbruzzese JL. Hidden biases in an observational study of bevacizumab beyond progression. J Clin Oncol. 27(10):1732-1733, 4/2009. PMID: 19255299.

Grant & Contract Support

Title: Institute for Pancreatic Cancer Research (PP-4)
Funding Source: Khalifa Bin Zayed Nahyan Foundation
Role: Principal Investigator-MDACC
Duration: 8/13/2010 - 8/12/2014
 
Title: Pancreas Cancer Direct Xenograft Program at MDAC
Funding Source: Viragh Foundation
Role: Principal Investigator-MDACC
Duration: 1/10/2010 - 12/31/2015
 
Title: Phase I Study of the BikD Nanoparitcle for Advanced Cancer of the Pancreas
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Milind Javle
Duration: 4/14/2009 - 3/31/2011
 
Title: SPORE in Gastrointestinal Cancer (PP-1)
Funding Source: NIH/NCI
Role: Project Co-Leader
Principal Investigator: Gerner
Duration: 8/1/2005 - 3/31/2013
 
Title: Early detection of Pancreatic Cancer (PP-1)
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Ann M Killary
Duration: 9/28/2004 - 6/30/2010
 
Title: SPORE in Pancreatic Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/30/2003 - 6/30/2010
 
Title: Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Razelle Kurzrock, M.D.,
Duration: 2/1/2003 - 1/31/2008
 
Title: Phase I Studies of Targeted Anti-Cancer Therapies
Funding Source: NIH/NCI
Role: Co-Program Leader
Principal Investigator: Kurzrock
Duration: 2/1/2003 - 1/31/2008
 
Title: U10 Full Member Application Affiliated with SWOG
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Eng
Duration: 7/26/2001 - 12/31/2015
 
Title: Targeted Assessment of Antiangiogenic Therapy
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/16/2001 - 12/31/2008
 
Title: Research Training in Academic Medical Oncology
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Hong
Duration: 9/30/1994 - 4/30/2016
 
Title: Cancer Center Support Grant (PP-RP7)
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Mendelsohn
Duration: 7/1/1978 - 6/30/2013

Last updated: 12/13/2012